GlassScriptPhysician profile
Jasmeet Kaur Mehta
NPI 1881048676
$1,703.12
in general payments reported to CMS, 2019-2025
24 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $215 · 2024: $670 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $238.43 | 2025 | Fasenra, Farxiga, Airsupra |
| Novo Nordisk INC | $233.37 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $195.65 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $182.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $94.62 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $88.70 | 2023-2025 | Repatha, Otezla, Repatha |
| Medtronic, INC. | $84.95 | 2025 | Inceptiv, Vanta Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.57 | 2024-2025 | Jardiance, Synjardy |
| Pfizer INC. | $68.13 | 2023-2025 | |
| Dexcom, INC. | $53.14 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $51.24 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.29 | 2023-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $40.05 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $37.96 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $32.17 | 2025 | Opsumit, Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.74 | 2023-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $30.02 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $21.83 | 2024 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $20.93 | 2025 | Thinprep 2000 Processor, Aptima |
| Biocomposites INC | $20.25 | 2024 | |
| Bausch Health US, LLC | $18.92 | 2025 | Wellbutrin |
| Merck Sharp & Dohme LLC | $15.97 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Xeris Pharmaceuticals, INC. | $13.40 | 2024 | Gvoke Hypopen |
| Impulse Dynamics (USA) INC. | $10.78 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmeet Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.